Axcella Health Inc. Stock Price, News & Analysis

Axcella Therapeutics (Nasdaq: AXLA) reported Q1 2022 financial results, highlighting a net loss of $19 million ($0.46 per share), compared to a $15.2 million loss in Q1 2021. Cash and equivalents increased to $63.2 million, bolstered by a $25 million stock offering. R&D expenses rose to $13.5 million due to ongoing clinical trials for Long COVID and NASH. The company aims to leverage federal initiatives for new Long COVID therapies, indicating a strategic focus on multi-targeted therapies for complex diseases.

Axcella Therapeutics (AXLA) has completed a $25 million registered direct stock offering priced at $1.91 per share, enhancing its balance sheet. The company initiated a Phase 2a clinical trial for Long COVID and received Fast Track designation from the FDA for AXA1125 in treating NASH with liver fibrosis. Axcella reported a net loss of $64.6 million for 2021, up from $56.5 million in 2020. The firm anticipates significant data from Long COVID and NASH trials in Q3 2022, suggesting a potentially transformative year ahead.

Axcella Therapeutics (Nasdaq: AXLA) has announced plans to report its financial results for Q4 and year-end 2021 on March 30, 2022. The company will hold a conference call at 8:30 a.m. ET to discuss the results and other business updates. Investors can access the call via telephone or through a webcast on Axcella's website. The company focuses on developing multi-targeted endogenous metabolic modulator compositions for complex diseases, including Long COVID and non-alcoholic steatohepatitis.

Axcella Therapeutics (Nasdaq: AXLA) has entered into a registered direct offering, selling 13,089,002 shares of common stock at $1.91 per share, resulting in gross proceeds of $25.0 million. The offering is expected to close on March 16, 2022. Proceeds will be used for various clinical trials, including Long COVID Phase 2a and NASH Phase 2b, as well as for working capital. This offering follows a previously filed shelf registration statement with the SEC, effective since June 12, 2020.

Axcella Therapeutics (Nasdaq: AXLA) has received Fast Track Designation from the FDA for AXA1125, aimed at treating non-alcoholic steatohepatitis (NASH) with liver fibrosis. This designation can expedite drug development and review processes. The company is currently enrolling participants in its EMMPACT℠ Phase 2b clinical trial, with interim results anticipated in mid-2022. Given that NASH affects millions and lacks approved treatments, AXA1125 is positioned to address a significant unmet medical need, potentially becoming a first-line therapy.

Axcella Therapeutics (Nasdaq: AXLA) announced management's participation in the SVB Leerink Global Healthcare Conference, with a fireside chat scheduled for February 17, 2022, at 9:20 a.m. ET. The live webcast will be available on Axcella's website and will remain accessible for 90 days post-event. Axcella is a clinical-stage biotechnology firm focused on treating complex diseases through novel endogenous metabolic modulator (EMM) compositions, targeting conditions such as hepatic encephalopathy, Long COVID, and non-alcoholic steatohepatitis (NASH).

Axcella Therapeutics (Nasdaq: AXLA) announced the appointment of Robert Crane as its new Chief Financial Officer. Crane brings over 35 years of experience in life sciences, having raised over a billion dollars in capital and contributing significantly to previous companies' successes. Axcella's President, Bill Hinshaw, emphasized Crane's financial expertise and operational mindset at a pivotal moment for the company as it advances its clinical programs. Axcella aims to share crucial clinical data later this year, which may positively impact investor sentiment and facilitate growth opportunities.

Axcella Therapeutics (NASDAQ: AXLA) announced key clinical milestones for 2022, including top-line data for its Long COVID Phase 2a trial expected mid-year and interim data from the EMMPACT Phase 2b trial for NASH. The company is advancing AXA1125, which targets mitochondrial energetics and inflammation and aims to engage with regulatory authorities upon positive data. Axcella also plans to update on the EMMPOWER Phase 2 trial for overt hepatic encephalopathy (OHE) and is focused on completing patient enrollment for its ongoing studies.

Axcella Therapeutics (Nasdaq: AXLA), a clinical-stage biotechnology firm, announced that its CEO, Bill Hinshaw, will present at the H.C. Wainwright BioConnect Conference on January 10, 2022, at 7:00 a.m. ET. The presentation will focus on Axcella's innovative approach to treating complex diseases with multi-targeted endogenous metabolic modulator compositions. A webcast of the event will be available on the company's website and can be accessed for 90 days post-event. Axcella's pipeline includes therapies for overt hepatic encephalopathy, Long COVID, and non-alcoholic steatohepatitis.